Diane Reidy-Lagunes, MD, Memorial Sloan-Kettering Cancer Center

Looking toward the future management of neuroendocrine tumors, Diane Reidy-Lagunes, MD, shares insight on possible therapy evolutions and ongoing unmet needs.

Considerations for use of surufatinib in patients with neuroendocrine tumors in light of the SANET-p and SANET-ep clinical trials.

Expert reflections on VEGF-targeted therapy’s role in the treatment of patients with neuroendocrine tumors.

Diane Reidy-Lagunes, MD, outlines goals of therapy and selection of systemic therapy for patients with neuroendocrine tumors.

A detailed explanation on how disease and patient factors inform selection from the treatment armamentarium for neuroendocrine tumors.

Standard treatment pathways for patients with neuroendocrine tumors involving systemic therapy, surgery, and radiation.

Expert insight on the pathogenesis of neuroendocrine tumors and the best use of molecular testing to inform treatment decisions.

Diane Reidy-Lagunes, MD, provides an overview of neuroendocrine tumors, along with specific considerations for optimal diagnosis and prognostication.